AstraZeneca plans to increase investment and scope of Virginia facility
AstraZeneca will invest USD 4.5 billion in its new manufacturing facility in Virginia, a proposed increase of USD 500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments.
This is part of the previously announced USD 50 billion investment.
3,600 jobs
The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect jobs, states the company.
The manufacturing facility is expected to create 600 highly skilled jobs including engineers, scientists, process facilitators which includes an additional 100 jobs as a result of the expansion. A further 3,000 jobs will be created to support the construction of the facility including engineers, skilled trades and construction workers. It will be at the forefront of technological innovation, leveraging AI, automation, and data analytics to optimize production.
Expanded the scope
The new facility will produce drug substance for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The company is now also announcing that it has expanded the scope to also include manufacturing for its antibody drug conjugate (ADC) cancer portfolio.
Updated: October 14, 2025, 11:07 am
Published: October 10, 2025
